In the United Kingdom, routine universal screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency in newborns is not standard practice. However, testing for G6PD deficiency is considered clinically indicated in newborns presenting with significant hyperbilirubinaemia, especially when assessing for underlying causes of jaundice. This includes taking into account the baby's ethnic origin as a risk factor for G6PD deficiency. Testing is part of a broader assessment that may include serum bilirubin, blood packed cell volume, blood group, and direct antiglobulin test (DAT) among others. The decision to test for G6PD deficiency is therefore targeted rather than universal, focusing on babies with clinical signs such as significant jaundice or prolonged jaundice, or those from at-risk ethnic groups.
For at-risk populations, such as those with ethnic backgrounds known to have a higher prevalence of G6PD deficiency, testing is considered when clinically indicated, particularly in the context of neonatal jaundice assessment. There is no explicit recommendation for routine screening of all newborns or asymptomatic individuals in these populations, but clinical vigilance and targeted testing are advised.